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INTRODUCTION  
Despite the availability of effective anti-TB antibiotics for the past half century, TB remains an 
important global health problem causing an estimated 9 million active TB cases and 1.5 million deaths 
annually (Link 3). The high mortality rate and widespread emergence of multi-drug resistant TB (MDR-
TB) and a very thin new TB drug pipeline
2
 signal an urgent need for new TB therapeutic strategies that 
could address the many unmet clinical needs.  Health services globally face major barriers to achieving 
optimal TB treatment outcomes using current WHO recommended TB drug treatment regimens. These 
include: the relentless spread of multidrug-/extensively drug- resistant TB (MDR-/XDR-TB); complex and 
toxic treatment regimens for MDR-TB; HIV-co-infection; pharmacokinetic interactions between TB 
drugs and anti-retroviral drugs; relapse following cure; permanent damage to lung and other tissues; 
long-term functional disability; immune reconstitution inflammatory syndrome (IRIS); and co-morbidity 
with non-communicable diseases such as diabetes and chronic obstructive airways disease. Another 
fundamental problem is the long duration of TB drug treatment (six months for drug sensitive TB and at 
least 18 months for drug resistant TB) to achieve a cure. This is due to M.tb achieving a dormant state 
which renders non-replicating M.tb phenotypically resistant to classes of anti-TB drugs that target M.tb 
replication for their action. For the past 60 years efforts at developing new treatment have focused on 
development of new TB drugs and regimens which target M.tb but not the host response or M.tb-host 
interactions resulting in tissue damage. However, recently attention has focused on investigating a 
raŶge of adjuŶĐt treatŵeŶt iŶterǀeŶtioŶs ǁhiĐh aiŵ to target the host respoŶse, kŶoǁŶ as ͚Host 
DireĐted Therapies͛ (HDTs). We highlight the rationale for HDTs, the current portfolio of HDTs, their 
possible mechanisms of action and the urgent need for their evaluation in clinical trials, is discussed. 
  
RATIONALE FOR HDTS  
HDTs aim to augment anti-M.tb protective immune mechanisms and/or directly reduce the excess 
inflammation, prevent end organ tissue damage, repair damaged tissues, preserve lung function, and 
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enhance the effectiveness of TB drug therapy by eliminating M.tb. HDTs may also have additional 
advantages for patients with TB/HIV co-infection since HDTs will have no interaction with ARVs with TB 
or acquired drug resistance, and may reduce development of IRIS and death. It is also hoped that by 
using these HDTs as adjunct to anti-TB chemotherapy, the combination could lead to fulfilling the 
unmet clinical needs by reducing the duration of therapy, and achieving better treatment outcomes, 
lowering the risk of developing further drug resistance and decreasing relapse or re-infection.  
Development of HDTs for TB
3
 and are focused on two general approaches: a) Modulating host 
inflammatory pathways to reduce aberrant or excessive inflammation and lung tissue destruction, b) 
Augmenting components of the host innate and adaptive immune effector mechanisms. A range of 
interventions with immunomodulatory effects are under investigation for use as HDTs (Supplementary 
online Table 1) for adjunct TB treatment. These include '‘epurposed͛ commonly used drugs for 
arthritis, lowering cholesterol, diabetes, antibiotics, epilepsy and cancer with no direct anti-M.tb 
activity; other products with immune-modulatory effects such as micronutrients and environmental 
mycobacteria; ͚Cellular therapy͛ ǁith ŵeseŶĐhǇŵal stroŵal Đells deriǀed froŵ patieŶt͛s oǁŶ ďoŶe 
marrow to reduce damaging inflammation, regenerating damaged tissues and inducing anti-M.tb 
immune responses; Therapeutic vaccines; Immunosuppressive drugs  which  re-activate dormant M.tb 
bacilli by changing metabolic state, thus increasing M.tb susceptibility to anti-TB drugs; Products 
targeting pathology due to both M.tb and HIV. 
 
 
HDTs READY FOR EVALUATION 
Repurposed drugs: Several drugs with potential for repurposing as HDTs already have well-defined 
safety and pharmacokinetic profiles and are ready to progress to randomized, controlled clinical trials 
that evaluate their effectiveness in TB, TB–HIV co-infection and TB co-morbid with other diseases (see 
Supplementary information S1 (table). 
Vitamin D induces the expression and release of innate antimicrobial peptides such as cathelicidin, and 
its effects can be enhanced by combining it with the histone deacetylase inhibitor phenylbutyrate. The 
diabetes drug metformin enhances macrophage autophagy by promoting phagolysosome fusion and 
increasing mitochondrial production of reactive oxygen species, and also induces expression of AMP-
activated protein kinase, leading to reduced TB load and lung pathology. Several non-steroidal anti-
inflammatory drugs (NSAIDs) reduce inflammation and tissue pathology, and also have potential to 
benefit patients who are co-infected with TB and HIV, and those who develop IRIS. The antibacterial 
drug doxycycline is a matrix metalloproteinase inhibitor that may protect against the degradation of 
collagen and other structural proteins in lung tissue. Statins such as simvastatin and rosuvastatin have 
anti-inflammatory effects, and induce autophagy and maturation of phagosome. The cancer drug 
Imatinib (Gleeeac-a tyrosine kinase inhibitor) activates autophagy and inhibits M.tb replication in 
macrophages by enhancing macrophage apoptosis and acidification. 
Other drugs which require further evaluation in animal or tissue models before entering human clinical 
trials, and their mechanisms of action are listed in Supplementary Table 1: 
Cell based therapies. Mesenchymal stromal cells (MSCs) derived from the patieŶt͛s oǁŶ ďoŶe ŵarroǁ 
may have the potential to modulate aberrant immune responses through their anti-inflammatory and 
tissue-repairing effects. MSCs exposed to a pro-inflammatory environment, such as high TNF-alpha 
levels in lungs, produce prostaglandin E2 (PGE2) limiting excess of type I – interferon production which 
is linked to disease exacerbation and increased M.tb proliferation. Adjunct therapy using MSCs derived 
froŵ the patieŶt͛s oǁŶ ďoŶe ŵarroǁ aŶd eǆpaŶded ex vivo before re-infusion, is  currently being 
trialed to improve management outcomes in both HIV-infected and uninfected individuals with MDR-
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TB.  Infusion of MSCs in a phase 1 trial in Belarus patients with MDR-TB/XDR-TB was found to be safe, 
and a phase 2 trial is underway in Durban, South Africa. Adjunct cellular therapy using autologous MSCs 
could be useful as for treatment of a range of inflammatory disorders including TB pericarditis, IRIS and 
miliary TB.  
 
CLINICAL TRIALS EVALUATION PLANS FOR HDTs  
Since the repurposed drug are have well-defined safety and pharmacokinetic profiles their individual   
evaluations through randomized controlled clinical trials are required to define their  effectiveness in 
all forms of clinical TB, TB/HIV co-infected patients and TB co-morbidities with other communicable 
diseases and non-communicable diseases.  The main aims would be to evaluate their effects on 
reducing duration of TB chemotherapy for both drug sensitive TB and MDR-TB, and on improving 
treatment outcomes (morbidity, mortality, relapse, lung function, and long term sequelae), inducing 
protective immune responses, reducing inflammation, and on tissue repair/regeneration. These trials 
will also allow for biomarkers of the effects of HDTs to be developed and validated.   
Phase 2b/phase 3 trials using several repurposed drugs (metformin, doxycycline, statins, NSAIDS) are 
currently being planned. Trials are underway for improved treatment outcomes for TB-IRIS with vitamin 
D with phenylbutryrate (Link 6), and with NSAIDS (Link 7). A multiple-arm, multiple-stage (MAMS), trial 
design would facilitate multiple evaluations for preparations from similar groups of HDTS such as re-
purposed drugs. Since a large numbers of trials, trials sites and patient cohorts are required to evaluate 
HDTs a multi-disciplinary, multi-country consortium with close engagement of end users and 
stakeholders will be required to take forward evaluations of HDTs.  At a stakeholders meeting held on 
7th April, 2015 in Cape Town (Link 8) held under the auspices of the SA-MRC the AFRICA- EUROPE HDT-
NET consortium of 29 African and 11 European country partners (Link 9) was launched.  The multi-
country, multidisciplinary consortium aim to conduct a range of RCTrials (some using the ͚MAMS͛ trial 
designs to allow for quicker exclusion or inclusion of adjunct therapies) of several ͚repurposed͛ drugs 
(Link 10). Central to the ethos of HDT-NET is to produce a high calibre cadre of African researchers 
(scientists, health and laboratory personnel) who will be suitably empowered to take leadership and 
conduct of high quality research and clinical trials. 
 
OUTLOOK  
A whole range of HDTs with the potential to meet unmet clinical needs for treatment of drug sensitive 
and drug resistant TB are becoming available. Further pre-clinical and clinical optimization studies are 
required for the large numbers of drugs which show promise for being repurposed as HDTs for adjunct 
TB therapy.  Current funder and pharma focus on new TB drug development needs to be complimented 
by further research  which should focus on discovery of HDTs which can overcome the ability of M.tb to 
arrest the normal progress of phagosome maturation.
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This should include new anti-M.tb agents that 
are regulators of cellular processes such as growth and proliferation, glucose metabolism, apoptosis, 
and autophagy and restrict M.tb growth in macrophages include kinase modulators, G-protein coupled 
receptor modulators, ion channel inhibitors, membrane transport proteins, and anti-inflammatory 
drugs.
5
 Closer collaborations between funders, drug developers, basic science, translational clinical 
research and clinical trials researchers are required to identify other candidates for HDTs from existing 
drugs and newer adjunct therapies. Increased donor funding into development and evaluation of novel 
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